Cipla’s unaudited financial results for the quarter ended June 30, 2013 (Q1) record a gross revenues growth of 25.3 per cent to Rs 2492 crore, up from Rs1989 crore. Operating margins grew by 24.8 per cent to Rs 675 crore, up from Rs 541 crore while profit after tax grew by 18.5 per cent to Rs 475 crore, up from Rs 401 crore
Operating margins increased by 24.8 per cent and is at 27.1 per cent of income from operations during Q1 FY1314. Profit after tax increased by 18.5 per cent to Rs 475 crore during Q1 FY1314 as compared to Rs 401 crore during Q1 FY1213.
Domestic revenues grew by 16.7 per cent to Rs 1132 crore during this quarter, up from Rs 970 crore during Q1 FY1213. The growth in domestic revenues was largely on account of growth in anti-asthma, antibiotics/infectives, and cardiovascular therapy segments.
On the international business front, exports of formulations grew by 27.7 per cent to Rs 1034 crore during Q1 FY1314, up from Rs 810 crore during Q1FY1213. Exports of APIs fell by 13.1 per cent to Rs 146 crore during Q1 FY1314, from Rs 168 crore during Q1 FY1213.
The growth in export revenues was primarily due to growth in anti-retroviral, anti-asthma and anti-allergic segments.
EP News Bureau